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Acrylamide inhibits long‑term
potentiation and learning involving
microglia and pro‑inflammatory
signaling
Yukitoshi Izumi1,2*, Chika Fujii1, Kazuko A. O’Dell1,2 & Charles F. Zorumski1,2
Acrylamide is a chemical used in various industries and a product following high-temperature
cooking of vegetables containing asparagine. Environmental or dietary exposure to acrylamide
could impair cognitive function because of its neurotoxicity. Using rat hippocampal slices, we tested
whether acrylamide alters induction of long-term potentiation (LTP), a cellular model of learning
and memory. We hypothesized that acrylamide impairs cognitive function via activation of proinflammatory cytokines because robust upregulation of NLRP3 inflammasome has been reported.
Although acrylamide up to 3 mM did not alter basal synaptic transmission, incubation with 10 μM or
acute administration of 100 μM acrylamide inhibited induction of LTP. Inhibitors of toll-like receptor 4
(TLR4), and minocycline, an inhibitor of microglial activation, overcame the effects of acrylamide on
LTP induction. Furthermore, we observed that acrylamide failed to inhibit LTP after administration
of MCC950, an inhibitor of NLRP3, or in the presence of Interleukin-1 receptor antagonist (IL-1Ra).
We also found that in vivo acrylamide injection transiently impaired body weight gain and impaired
one-trial inhibitory avoidance learning. This learning deficit was overcome by MCC950. These results
indicate that cognitive impairment by acrylamide is mediated by mechanisms involving microglia and
release of cytokines via NLRP3 activation.
Abbreviations
ACR	Acrylamide
ACSF	Artificial cerebrospinal fluid
ANOVA	Analysis of variance
APV	2-Amino-5-phosphovareic acid
BBB	Blood brain barrier
CNQX	6-Cyano-7-nitroquinoxaline-2,3-dione
CNS	Central nervous system
EPSP	Excitatory postsynaptic potentials
HFS	High frequency stimulation
IACUC	Institutional Animal Care and Use Committee
IL-1	Interleukin-1
IO	Input–output
i.p.	Intraperitoneally
IR-Ira	Interleukin-1 receptor antagonist
LFS	Low-frequency stimulation
LPS-RS	Lipopolysaccharide from Rhodobacter sphaeroides
LTD	Long-term depression
LTP	Long-term potentiation
mtROS	Mitochondrial reactive oxygen species
NIH	National Institute of Health
NLRP3	NOD-, LRR- and pyrin domain-containing protein 3
NMDAR	N-methyl-D-aspartate receptor
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P	Postnatal day
PTP	Post-tetanic potentiation
TNF-α	Tumor necrosis factor-ɑ
Acrylamide (ACR), or 2-propenamide, is a vinyl monomer with the molecular formula C
 3H5NO and is widely
used to make polyacrylamide, which is used in treating waste water discharge and in industrial processes. In
addition, acrylamide and polyacrylamides are used in production of dyes and organic chemicals, contact lenses,
cosmetics and toiletries, permanent-press fabrics, paper and textile production, pulp and paper production,
ore processing, sugar refining, and as a chemical grouting agent and soil stabilizer for construction of tunnels,
sewers, wells and reservoir1.
While occupational and environmental exposures to ACR have long been a concern2, ACR is also a byproduct in the Maillard reaction via condensation of reducing sugars and amino acids such as asparagine, a
major amino acid in potatoes, in the process of cooking at high temperatures3,4. Thus, excessive dietary intake
of ACR in foods such as French fries and potato chips is also a concern for human health.
Exposure to ACR is harmful because of its neurotoxicity, reproductive toxicity, genotoxicity and
carcinogenicity5. Peripheral neuropathy has been described in workers chronically exposed to ACR6. In addition, damage to the central nervous system (CNS) has also been r eported7,8. Cognitive decline is also suggested
in elderly people who ingest greater amounts of ACR over a number of y ears9, suggesting that dietary exposure
may cause CNS problems. Indeed, 16 week exposure to ACR in drinking water worsens cognitive deficits in
mice10 and more chronic exposure (12 months) in rats results in neuronal deficits in the hippocampus and cortex
accompanied with poor performance in spatial memory t ests11.
Although mechanisms underlying ACR neurotoxicity are not fully understood, several hypotheses have been
proposed, including inhibition of kinesin-based fast axonal transport, alteration of neurotransmitter levels, and
direct inhibition of n
 eurotransmission12. More recently, the possible involvement of inflammatory reactions in
ACR toxicity is postulated. In animal models, increased levels of circulating lipopolysaccharide (LPS), interleukin-1ß (IL-1β) and tumor necrosis factor-ɑ (TNF-α) after dietary e xposure10 or robust upregulation of protein
levels of nucleotide-binding oligomerization domain-3 (NLRP3) inflammasome constituents including NLRP3,
caspase-1 and IL-1β after dietary e xposure11 were observed. Furthermore, Sui et al. found that 24 h administration of 2.5 mM ACR increases levels of NLRP3 inflammasome constituents in BV2 microglia, suggesting that
effects of ACR on NLRP3 can be a cute13. Interestingly, these changes were inhibited by MCC950, an inhibitor
of NLRP3 activation and inflammasome f ormation14.
Taken together, it appears that ACR acutely impairs cognitive functions through direct activation of NLRP3 in
the CNS. Using rat hippocampal slices, we examined whether brief exposure to ACR impairs long-term potentiation (LTP), a cellular mechanism of learning and memory, and the possible involvement of pro-inflammatory
activation in its acute toxicity.

Methods

Animals. Sprague–Dawley albino rats were obtained from Harlan Laboratories (Indianapolis IN) and were
housed in approved facilities at Washington University. Animal use followed National Institute of Health (NIH)
guidelines and was approved by the Washington University Institutional Animal Care and Use Committee
(IACUC). The reporting in the manuscript follows the recommendations in the ARRIVE guidelines.
Hippocampal slice preparation and physiology.

Hippocampal slices were prepared from postnatal
day (P) 28–32 male albino rats using previously described m
 ethods15. Dissected hippocampi were pinned on
an agar base in ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): 124 NaCl, 5 KCl, 2 MgSO4, 2
CaCl2, 1.25 N
 aH2PO4, 22 NaHCO3, 10 glucose, bubbled with 95% O2–5% C
 O2 at 4–6 °C. The dorsal two-thirds
of the hippocampus was cut into 500 µm slices using a rotary slicer. Acutely prepared slices were kept in an incubation chamber containing gassed ACSF for at least 1 h at 30 °C before experiments.
For electrophysiological studies, slices were transferred to a submersion-recording chamber at 30 °C with
ACSF and perfused continuously at 2 ml/min. Extracellular recordings were obtained from the apical dendritic
layer (stratum radiatum) of area CA1 for monitoring excitatory postsynaptic potentials (EPSPs) with electrodes
filled with 2 M NaCl (5–10 MΩ resistance).
Because LTP is a synaptic phenomenon, we focused on recordings of EPSP slope. EPSPs were evoked using
0.1 ms constant current pulses through a bipolar stimulating electrode in the Schaffer collateral (SC) pathway.
Responses were monitored by applying single stimuli every 60 s at half-maximal intensity based on a control
input–output (IO) curve. In some slices, we also examined the paired pulse ratio evoked by two stimuli at 21 ms
interval to detect changes in probability of presynaptic vesicular release. After obtaining stable baseline recordings for at least 10 min, LTP was induced by a single 100 Hz × 1 s high frequency stimulation (HFS) using the
same intensity stimulus. Following HFS, responses were monitored by single stimuli once per minute during
the period of post-tetanic potentiation (PTP) and then every five minutes for the remainder of an experiment.
For display purposes, graphs show data every 5 min except during initial post-tetanic potentiation. In some
experiments, long-term depression (LTD) was induced by 1 Hz × 900 pulse low frequency stimulation (LFS)16.
Isolated EPSPs mediated by N-methyl-D-aspartate receptors (NMDAR)s were recorded at very low frequency
SC stimulation (1/min) in ACSF containing 0.1 mM M
 g2+ and 2.5 mM C
 a2+ to promote NMDAR activation
and 30 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), to eliminate the contribution of AMPARs16. This
NMDA-EPSP is completely blocked by 2-amino-5-phosphovareic acid (APV), a selective NMDAR a ntagonist17.
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Figure 1.  ACR does not alter basal synaptic transmission in the CA1 region of hippocampal slices. (A) In
5 slices, the concentration of ACR was raised step by step every 15 min. EPSPs, evoked by stimulation of
the Schaffer collateral pathway, were not altered by ACR up to 3 mM. (B) Similarly, paired pulse depression
normally observed at 21 ms was not altered by ACR up to 3 mM. (C) In different slices, NMDAR-mediated
synaptic responses recorded in low magnesium were not altered by 100 μM ACR.

Injection of acrylamide and behavioral studies. Rats were tested for memory acquisition in a one-trial

inhibitory avoidance learning task18–20. This task reflects explicit-declarative fear memories and has been associated with hippocampal LTP; the task is relatively simple to administer with high reliability and clear behavioral
endpoints21–23. The testing apparatus consists of two chambers, only one of which is lit. Both compartments
have a floor of stainless steel rods (4 mm diameter, spaced 10 mm apart) through which an electrical shock
could be delivered in the dark chamber (12 × 20 × 16 cm). The adjoining lit compartment (30 × 20 × 16 cm) was
illuminated with four 13 W lights. Light intensity in the lit chamber was 1000 lx while that in the dark chamber
was < 10 lx. On the first day of testing, rats were placed in the lit chamber and allowed to habituate to the apparatus by freely moving between chambers for 10 min without any foot shocks being administered. On the next
day, mice were administered ACR (100 mg/kg ip) or vehicle (saline) 1 h prior to training. MCC950 (50 mg/kg
ip) was injected 24 h and 2 h before ACR administration. It has been reported that one time injection of a similar
dose of acrylamide to rats induces neurological sequelae24. At the time of training, animals were initially placed
in the lit compartment and allowed to explore the apparatus freely for up to 300 s (5 min). When rats completely
entered the dark chamber, they were immediately given a foot shock. Upon returning to the lit chamber, rats
were removed from the apparatus and returned to their home cages. On the next day of testing, rats were placed
in the lit chamber without any drug treatment and the latency to enter the dark compartment was recorded over
a 300 s trial.

Chemicals. TAK-242 (CAS 243984-11-4 Cat 6587/5) was from R&D Systems (Minneapolis MN). LPS-RS
(from Rhodobacter sphaeroides, Catalog # tlrl-rslps) and MCC950 (CAS 210826-40-7, Catalog # inh-mcc) were
purchased from InvivoGen (San Diego CA). Other chemicals, including minocycline (CAS 13614-98-7, Cat#
M2280000) and IL1-Ra (Cat# SRP 3084), and salts were obtained from Millipore Sigma Chemical Company.
Drugs were prepared as stock solutions in either ACSF or DMSO and diluted to final concentration at the time
of experiment. The concentrations of TAK-242, LPS-RS and minocycline are based on our previous studies using
those inhibitors against L
 PS23. The dose and concentrations of MCC950 and IL1-Ra followed studies by Coll
et al.14 and Edy et al.25, respectively.
Statistical analysis. Physiological data were collected and analyzed using PClamp software (Molecular

Devices, San Jose CA). Data are expressed as mean ± SEM 60 min following HFS, and are normalized with
respect to initial baseline recordings (taken as 100%). Statistical comparisons in physiological studies were based
on IO curves at baseline and sixty minutes following HFS to determine the degree of change in EPSP slope at
the 50% maximal point with p < 0.05 considered significant. Data in figures for physiological studies are from
continuous monitoring of EPSPs at low frequency during the course of experiments and thus may differ from
numerical results described in the text, which represent analyses based on comparison of input–output curves.
Statistics were performed using commercial software (GraphPad Prism 9.2.0, GraphPad Software, La Jolla California). For comparisons of LTP results with 100 µM ACR alone, or one-trial learning after injection of 100 mg/
kg ACR, data were analyzed by two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. In other studies, a two-tailed Student’s t-test was used for comparisons between groups. In cases of
non-normally distributed data, the non-parametric Wilcoxon Rank Sum Test was used.

Results

ACR inhibits hippocampal LTP. In initial studies, we examined acute exposure to ACR in ex vivo hippocampal slices to determine effects on synaptic function and long-term plasticity in the CA1 region. When
ACR was perfused in increasing concentrations every 15 min, we observed no significant changes in baseline
transmission at concentrations up to 3 mM (N = 5, Fig. 1A). Using paired stimulation at an interval of 21 ms,

Scientific Reports |

(2022) 12:12429 |

https://doi.org/10.1038/s41598-022-16762-7

3
Vol.:(0123456789)

www.nature.com/scientificreports/

Figure 2.  ACR inhibits LTP, but not LTD, in the CA1 region of rat hippocampal slices. (A) Ten μM ACR when
administered for 4 h or more prior to and during slice recording (black bar) blocks LTP induction (black circles)
after a single 100 Hz × 1 s HFS (arrow). Control LTP in naive hippocampal slices is shown in white circles.
Traces to the right of this graph and in subsequent figures show representative EPSPs at baseline before HFS
(dashed traces) and 60 min following HFS (solid red lines). Calibration bar (Panel B): 1 mV, 5 ms. (B) Ten μM
ACR (black bar) does not inhibit LTD induction after LFS (hatched bar). Control LTD is shown in white circles.
Traces show representative EPSPs at baseline before LFS (dashed traces) and 60 min following LFS (solid red
lines).

we also analyzed whether ACR altered short-term plasticity. ACR did not significantly alter the ratio of the 2nd
EPSP slope to the 1st EPSP slope for either dendritic or somatic EPSPs at any concentration tested (p = 0.124,
one-way ANOVA, N = 5 per group, Fig. 1B). These studies indicate that ACR does not significantly affect basal
synaptic function at concentrations up to 3 mM. We also examined the effects of ACR on NMDA receptor
(NMDAR)-mediated synaptic responses because NMDAR activation is pivotal for induction of long-term
forms of synaptic plasticity in the CA1 region and inhibition of NMDA receptors would result in impairment
of synaptic plasticity. Administration of 100 μM ACR, however, did not acutely alter NMDAR-mediated EPSPs
(105.2 ± 9.3% after 30 min administration, N = 5 Fig. 1C).
We next examined whether ACR alters induction of long-term plasticity. In the absence of ACR, HFS consistently induced LTP in control slices (158.3 ± 4.6% of baseline measured 60 min after HFS, N = 5, Fig. 2A). To
examine effects of ACR on synaptic plasticity, we initially incubated slices with 10 μM ACR for 4–5 h. Since it
has been shown that some fried meals could contain over 10 μmol/kg ACR26, we started from this concentration.
Ten μM ACR was administered prior to delivering a 100 Hz × 1 s HFS (for LTP) or 1 Hz × 900 pulse LFS (for
LTD); these stimuli reliably induce long-term plasticity in control slices from P30 rats. Using this subacute ACR
exposure, LTP was not induced by HFS (96.5 ± 5.2% of baseline, N = 5), although LTD was successfully induced
by LFS (62.5 ± 5.2%, N = 4, Fig. 2A,B).
We also examined whether a shorter exposure to ACR alters LTP induction. Although 30 min administration
of 10 μM ACR did not inhibit LTP (133.1 ± 18.0%, N = 5, Fig. 3A), 100 μM ACR acutely inhibited LTP induction (97.7 ± 5.8%, N = 10, P = 0.0014 vs control, Fig. 3B). In another set of slices, LFS delivered following 30 min
administration of 100 µM ACR successfully induced LTD (52.7 ± 6.1%, N = 5, not shown), indicating again that
LTD is not affected by exposure to ACR.

ACR inhibits LTP via pro‑inflammatory pathways. Based on prior studies indicating that ACR can

evoke inflammatory r esponses11,13, we examined the role of pro-inflammatory pathways in the effects of ACR. To
test the involvement of pro-inflammatory signaling, we used TAK-242, a specific inhibitor of toll-like receptor 4
(TLR4), and LPSRS, an agent that also inhibits TLR4 in addition to non-canonical inflammasome activation23.
In the presence of 1 μM TAK-242, administration of 100 μM ACR did not inhibit LTP induction (156.9 ± 12.7%,
N = 9, P = 0.0014 vs. ACR alone, Fig. 4A). Similarly, 3 μg/ml LPSRS, overcame the inhibitory effects of ACR
(160.9 ± 11.5%, N = 5, P = 0.0007 vs. ACR alone, Fig. 4B). We then examined effects of minocycline, an inhibitor of microglial activation23. In the presence of 0.5 µM minocycline, 100 µM acrylamide failed to inhibit LTP
induction (138.7 ± 4.2, N = 6, P = 0.0277, Fig. 4C). These findings strongly suggest that TLR4 activation, likely in
microglia, is involved in ACR-mediated inhibition of LTP induction.
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Figure 3.  ACR acutely inhibits LTP in the CA1 region of rat hippocampal slices. (A) When administered
for 30 min, 10 µM ACR (gray bar) does not inhibit the induction of LTP in response to HFS (arrow) (gray
circles). (B) 100 µM ACR (black bar) acutely inhibits LTP (black bar). Traces to the right of these graphs
show representative EPSPs at baseline before HFS (dashed traces) and 60 min following HFS (solid red lines).
Calibration bar (Panel B): 1 mV, 5 ms.

One of the major consequences of TLR4 activation is stimulation of the NLRP3 inflammasome and release
of IL-127–30. Supporting this possibility, we observed that 100 μM ACR failed to inhibit LTP induction in the
presence of 0.5 μM MCC950, an inhibitor of NLRP3 (141.8 ± 17.5, N = 5, P = 0.0247 vs. ACR alone, Fig. 5A).
Similarly, 100 μM ACR did not block LTP in the presence of 100 ng/ml Interleukin-1 receptor antagonist (IL1Ra) (132.4 ± 9.3%, N = 8, P = 0.0492 vs. ACR alone, Fig. 5B).

ACR dampens learning via NLRP3 activation. In subsequent studies, we examined the effects of sys-

temic ACR on learning and memory using a one-trial inhibitory avoidance task that has been linked previously
to hippocampal L
 TP20. ACR was injected (100 mg/kg, i.p.) 24 h before conditioning. The increase in body weight
typically observed in juvenile (~ P30) rats was dampened by ACR one day after injection (P = 0.0002) though it
returned to control levels on the second day following ACR treatment (P = 0.8832, Fig. 6A). Rats exhibited no
noticeable changes in gait or coordination following ACR. ACR treatment had marked acute effects on performance in one-trial learning compared to saline-treated controls when tested 24 h after conditioning. The ACRinduced defect in learning was manifest by rats more readily entering the dark chamber where they had been
shocked, whereas controls remained in the lit compartment for the full duration of the trial P = 0.005, N = 8,
Fig. 6B).
In rats treated with MCC950 (50 mg/kg i.p. twice), similar dampening of body weight one day after injection
was observed but recovered to control levels on the second day (Fig. 6A). In spite of the effect on weight gain,
ACR did not impair one-trial learning after injection of MCC950 (P = 0.0454 vs. ACR alone, N = 8, Fig. 6B).

Discussion

A major finding in this study is the alteration of cognitive function 24 h after in vivo systemic administration
of ACR. Effects of ACR on learning and memory are not the result of gross changes in neurological function
because we also observed that systemic ACR had no clear effect on gait, activity or level of consciousness. We
did observe that ACR temporarily decreased weight gain by 24 h after administration, although ACR-treated
rats caught up with controls by 48 h after exposure. A decrease in weight gain was also observed previously in
mice treated with ACR13.
Cognitive impairment by ACR may be induced indirectly through chronic damage to the blood brain barrier
(BBB), and ACR slowly impairs transport and secretary functions of the B
 BB31. However, acute actions following
systemic injection suggest that some effects of ACR may be more direct in the CNS and may be detected shortly
after administration in ex vivo systems. Indeed, in hippocampal slices treated with 10 μM ACR for several hours,
LTP, a cellular model of learning and memory, was markedly impaired. If ACR is distributed equally in the CNS
after injection, the concentration of 10 μM suggests that single exposure at 100 mg/kg could have deleterious
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Figure 4.  TLR4 antagonists and minocycline overcome effects of ACR on LTP. (A) TAK 242 (white bar), a
TLR4 antagonist, allows LTP induction after HFS (arrow) in spite of the presence of 100 µM ACR (black bar).
(B) Similarly, LPSRS (white bar), another TLR4 antagonist, overcomes inhibitory effects of 100 µM ACR on LTP
induction. (C) At 0.5 µM, the microglial inhibitor, minocycline (white bar) also overcomes the inhibitory effects
of ACR (black bar) on LTP. Traces show representative EPSPs. Calibration: 1 mV, 5 ms.

effects on cognitive function. Although inhibitory effects on LTP induction are also observed when 100 μM
ACR was administered for 30 min prior to the delivery of HFS, concentrations of ACR as high as 3 mM did not
affect basal synaptic responses or short-term paired-pulse plasticity. These observations suggest that neurotoxic
effects of ACR, even after high dose exposure, can be relatively subtle since basic neuronal function is preserved.
In contrast, learning dysfunction can occur fairly soon after ACR exposure even if it is only a single exposure.
Learning disability is often difficult to detect because of lack of specific symptoms. Even if cumulative levels of
ACR are within a low micromolar range, however, learning difficulties may follow repeated consumption of ACR
rich foods or environmental exposures.
In the hippocampus, LTP and LTD require activation of NMDA receptors for induction. However, NMDAEPSPs were not altered by 100 μM ACR, indicating that inhibition of LTP induction by ACR is not through
block of NMDA receptors, and, consistent with this conclusion, ACR failed to alter LTD induction. LTP induction can be dampened by other stressors via different mechanisms. For instance, untimely activation of NMDA
receptors can inhibit LTP induction32. Similarly, toxic cellular stressors such as ethanol and acetaldehyde also
inhibit LTP induction19,33. Recently, we showed that ISRIB, an inhibitor of cellular integrated stress responses,
and GW 3965, an agonist for liver X receptors, do not alter NMDA responses but overcome inhibitory effects of
ethanol on CA1 synaptic p
 lasticity19. The NLRP3 inflammasome is also involved in stress r esponses34. Because the
integrated stress response controls production of mitochondrial reactive oxygen species (mtROS), and NLRP3
inflammasome activation by lipids35, it is plausible that cellular stress triggered by neurotoxins activates NLRP3.
Indeed, recent studies show potential roles of NLRP3 activation in ACR toxicity. In Kupffer cells, 0.5–1 mM ACR
induces ROS production in 24 h and increases expression of NLRP3 and IL-1β mRNA, which results in NLRP3
inflammasome formation36. In rats, chronic (12 month) exposure to ACR (5 mg/kg/day) markedly upregulates
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Figure 5.  An NLRP3 inhibitor and IL-1 receptor antagonist overcome effects of ACR on LTP. (A) Prolonged
administration of 0.5 μM MCC950, an inhibitor of NLRP3 for 2–4 h (white bar) prior to HFS (arrow) allows
LTP induction in spite of the presence of 100 µM ACR (black bar). (B) Similarly, in the presence of 100 ng/ml
Interleukin-1 receptor antagonist (white bar), ACR fails to block LTP induction. Traces show representative
EPSPs. Calibration: 1 mV, 5 ms.

Figure 6.  Effects of ACR ip injection in vivo. (A) In vivo administration of ACR (100 mg/kg ip) to young rats
results in weight loss next day, which is compensated the following day. Injection of MCC950 (50 mg/kg, 24 h
and 2 h before ACR administration) did not alter the change in weight gain. **p < 0.01 compared with control
by Student t-test. (B) ACR administered one day prior to inhibitory avoidance training results in a defect in
learning as manifest by rats more readily leaving the lit chamber to enter the dark chamber where they had
received a foot shock one day previously. The learning defect was overcome by administration of MCC950.
**p < 0.01.
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Figure 7.  Schematic diagram to show how humans are exposed to ACR and a possible mechanism how ACR
impairs cognitive function via activation of TLR4 and the NLRP3 inflammasome in microglia. Brown lines
show locations where inhibitors work.

protein levels of NLRP3 inflammasome constituents including NLRP3 caspase-1, and pro-IL-1β and IL-1β in
hippocampus and frontal cortex11.
Our results indicate that disruption of LTP by ACR is mediated by TLR4. Expression of TLR4 is not limited
to glia but is also observed in neurons, and activation of neuronal TLR4 results in liberation of tumor necrosis
factor-α (TNFα) and IL-637. In the present study, however, the action of ACR was clearly prevented by minocycline, which is commonly used to inhibit microglial a ctivation23, suggesting that disruption of LTP involves
microglia. The disruption of LTP by ACR also involves stimulation of pro-inflammatory signaling via the NLRP3
inflammasome. MCC950 specifically inhibits the NLRP3 i nflammasome38 and blocks canonical, non-canonical
and alternative NLRP3 activation14,39,40. Thus, MCC950 is a useful agent to prevent effects of ACR regardless of
the pathway by which ACR activates N
 LRP341. Sui et al. have shown that in BV2 microglia, 2.5 mM ACR for 24 h
triggers NLRP3 inflammasome activation and this activation is reversed by 0.1 μM M
 CC95013. They also showed
that gait abnormalities observed 7–10 days after ACR exposure were partially attenuated by MCC950, indicating
that NLRP3 inflammasome activation is involved in neurological sequelae. Furthermore, MCC950 also dampens
NLRP3 activation and cognitive impairment triggered by isoflurane in mice42. In the current study, we observed
that MCC950 prevents the inhibitory effects of ACR on LTP induction and one-trial avoidance learning. This
finding suggests that ACR impairs cognitive functions via NLRP3 inflammasome activation.
NLRP3 inflammasome activation results in secretion of both IL-1 and IL-18. In BV-2 microglia, ACR induces
overexpression of both c ytokines13,43. However, secretion of these cytokines differ in terms of activation pathway
and timing44,45. It is well known that IL-1 inhibits L
 TP46–48. Thus, it is possible that both cytokines are involved
in the inhibitory effects of ACR on LTP induction.
To examine whether IL-1 participates in the action of ACR, we used the interleukin-1 receptor antagonist
(IL-1Ra), which selectively binds IL-1 receptors without inducing intracellular r esponses49. Because it has been
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reported that IL-1Ra alone, given as an intracerebroventricular injection, could inhibit LTP induction in r ats47,
or because IL-1Ra may depotentiate established L
 TP50, IL-Ra was administered before, but not after HFS in the
current study. Similar to MCC950, IL-1Ra clearly prevented the inhibitory effects of ACR on LTP induction.
This result suggests a critical role for IL-1 in the inhibition of LTP induction following ACR exposure. Further
studies will be needed to determine whether there is also a role for IL-18. Possible mechanisms underlying how
ACR impairs cognitive function are summarized in Fig. 7.
Taken together, our results indicate that ACR can impair cognition and hippocampal function, in addition to
its other known effects as a carcinogen. Learning problems may result from excessive exposure to ACR through
activation of proinflammatory signaling (Fig. 7).

Ethical approval and consent to participate. The animals used in this study were housed in approved
facilities at Washington University. Animal use followed National Institute of Health (NIH) guidelines and was
approved by the Washington University Institutional Animal Care and Use Committee (IACUC).

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Received: 31 March 2022; Accepted: 14 July 2022
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